M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

Phase 1

Active, not recruiting

Conditions: Tumor
Adenocarcinoma

Interventions: Drug: Pembrolizumab
Drug: lenvatinib

First Posted Date: 2022-03-10

Last Posted Date: 2024-10-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 14

Registration Number: NCT05273554

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia

Phase 2

Active, not recruiting

Conditions: Leukemia
Acute Lymphoblastic Leukemia

Interventions: Drug: Mini-hyper CVD
Drug: Ponatinib
Drug: Venetoclax

First Posted Date: 2022-03-07

Last Posted Date: 2024-10-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 26

Registration Number: NCT05268003

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test

Phase 1

Terminated

Conditions: Metastatic Breast Cancer
Breast Cancer

Interventions: Drug: Neratinib
Drug: Capmatinib

First Posted Date: 2022-02-17

Last Posted Date: 2024-11-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT05243641

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Association Between Gut Microbiome and Dietary Determinants and Vaccine Response

Recruiting

Conditions: Influenza

Interventions: Procedure: Biospecimen Collection
Other: Questionnaire Administration

First Posted Date: 2022-02-14

Last Posted Date: 2024-11-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1000

Registration Number: NCT05239403

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer

Phase 2

Recruiting

Conditions: Breast Carcinoma

Interventions: Procedure: Computed Tomography
Radiation: Fluorine F 18 Fluorthanatrace
Procedure: Positron Emission Tomography

First Posted Date: 2022-02-07

Last Posted Date: 2024-12-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 36

Registration Number: NCT05226663

Locations: 🇺🇸
Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States
🇺🇸
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Mobile Phone Text-based Intervention to Reduce Sedentary Behavior and Engage Communities on the Importance of Healthy Lifestyles: the TEXT2MOVE Study

Not Applicable

Recruiting

Conditions: Life Style
Healthy Lifestyle

Interventions: Device: FitBit

First Posted Date: 2022-02-01

Last Posted Date: 2024-10-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 200

Registration Number: NCT05217108

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Oncology Dashboard for the Improvement of Operational Efficiency and Patients Outcomes in Patients With Sarcoma

Not Applicable

Active, not recruiting

Conditions: Sarcoma

Interventions: Other: Informational Intervention
Other: Best Practice
Other: Questionnaire Administration

First Posted Date: 2022-01-31

Last Posted Date: 2024-07-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 92

Registration Number: NCT05216029

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers

Recruiting

Conditions: Gastric
Gastrostomy
GastroEsophageal Cancer

Interventions: Other: Standard of Care
Other: Control Group

First Posted Date: 2022-01-25

Last Posted Date: 2024-10-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT05205343

Locations: 🇰🇷
Yonsei University College of Medicine, Soeul, Korea, Republic of
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇯🇵
Keio University School of Medicine, Tokyo, Japan

and more 1 locations

Positive Activities for Asian American Cancer Patients and Caregivers

Not Applicable

Completed

Conditions: Cancer

Interventions: Behavioral: Outside Contribution
Behavioral: Household Contribution
Behavioral: Control

First Posted Date: 2022-01-24

Last Posted Date: 2024-11-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT05203614

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases

Phase 1

Recruiting

Conditions: Metastases

Interventions: Drug: Yttrium-90 (Y-90) resin microspheres

First Posted Date: 2022-01-19

Last Posted Date: 2024-12-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT05195710

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy